BoHChaoMD

Oncology • New York, NY

Thoracic Cancer

Clinical Assistant Professor of Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Chao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chao's full profile

Already have an account?

Office
525 E 68th St
New York, NY 10065
Phone+1 212-746-5454

Summary

Dr. Bo Chao is an oncologist in New York, NY and is affiliated with NewYork-Presbyterian/Weill Cornell. He received his medical degree from University of Minnesota Medical School and has been in practice 19 years. He also speaks multiple languages, including Chinese (Mandarin). He specializes in thoracic cancer and is experienced in thoracic oncology and lung neoplasms.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2009 - 2011
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2005 - 2008
University of Minnesota Medical SchoolClass of 2005

Certifications & Licensure

NY State Medical License 2017 - 2026
OH State Medical License 2012 - 2019
WI State Medical License Active through 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
Active, not recruiting
Phase 3
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
Completed
Phase 1
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Start of enrollment: 2016 Oct 24
Completed
Phase 1
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 19
Terminated
Phase 2
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 22
Terminated
Phase 2
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Dec 20
Recruiting
Phase 3
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Start of enrollment: 2017 May 02
Recruiting
Phase 1, Phase 2
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Start of enrollment: 2023 Mar 14
Recruiting
Phase 3
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Start of enrollment: 2019 May 28
Active, not recruiting
Phase 2
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2024 Feb 08
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stagefusion-positive non-small cell lung cancer.
Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, Michael C Fishbein, Yonina R Murciano-Goroff
Frontiers in Oncology. 2023-01-01
11 citations
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIAfusion-positive non-small-cell lung cancer.
Masahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, Melissa L Johnson, Luis Paz-Ares
Future Oncology. 2022-09-01
32 citations
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Helena A. Yu, Luis Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido
Clinical Cancer Research. 2021-02-15

Professional Memberships

Other Languages

Chinese (Mandarin)

Industry Relationships

Senior Vice President, Puma Biotechnology2023 - Present
Executive Medical Director, Eli Lilly and Company2015 - 2023